Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Crivellari, D.
Right arrow Articles by Senn, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crivellari, D.
Right arrow Articles by Senn, H.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:769-776, 1995
© 1995 European Society for Medical Oncology

research-article

Routine tests during follow-up of patients after primary treatment for operable breast cancer

D. Crivellari9, K. N. Price13, M. Hagen1, A. Goldhirsch1,14, R. D. Gelber13, M. Castiglione1,12, A. S. Coates2, C.-M. Rudenstam3, J. Collins2, J. Lindtner4, H. Córtes-Funes5, A. Gudgeon6, E. Simoncini10, M. Byrne2, H. G. Schniirch7, M. Fey1, M. H. N. Tattersall2, J. F. Forbes2, F. Cavalli1, R. Reed2 and H.-J. Senn1

1Swiss Group for Clinical Cancer Research (SAKK)
2Australia New Zealand Breast Cancer Trials Group (ANZ-BCTG)
3West Swedish Breast Cancer Study Group Göteborg, Sweden
4The Institute of Oncology Ljubljana, Slovenia
5Madrid Breast Cancer Group Spain
6Groote Schuur Hospital Cape Town, S. Africa
7West German Tumor Center Essen, Germany
8The Royal Free Hospital London, U.K.
9Centro di Riferimento Oncologico Aviano, Italy
10Spedali Civili & Beretta Foundation Brescia, Italy
11University of Düsseldorf Germany
12IBCSG Coordinating Center Bern, Switzerland
13IBCSG Statistical & Data management Centers Boston, MA, Amherst, NY, U.S.A.

14Correspondence to: Aron Goldhirsch, M.D. International Breast Cancer Study Group Statistical Center Dept of Oncology Ospedale Civico 6900 Lugano Switzerland

Background: Follow-up tests for patients after diagnosis and primary treatment of breast cancer are routinely performed. However, the usefulness of these follow-up parameters remains unclear. We determined the yield of a variety of blood tests used to detect the presence of overt metastatic disease

Methods: 4105 patients enrolled in International (Ludwig) Breast Cancer Study Group (IBCSG) randomized clinical trials from 1978 to 1985 were analyzed for abnormal or equivocal findings in six routine blood tests obtained every 3 months for the first two years, every six months for years 3–5 and yearly thereafter. The relationship of test results to the occurrence of overt metastatic disease was evaluated. The relapses were categorized as follows in order to estimate the yield of the different tests for relevant sites of metastases: any breast cancer relapse, bone ± other; liver ± other

Results: Alkaline phosphatase alone was abnormal in a high proportion of patients with either bone metastases, liver metastases, or both. SGOT and gamma-GT were also sensitive for patients with liver metastases. Bilirubin, serum calcium, and serum creatinine were relatively insensitive indicators of relapse. Abnormal test results were reported sometime during a patient's disease-free period for 3% to 6% of patients, depending on the test

Conclusions: Alkaline phosphatase was the most effective blood test to distinguish patients with relapse from those without relapse. It is inexpensive and its yield is relatively high for predicting liver and bone metastases. The routine use of the other tests analyzed to detect metastases was not justified

breast cancer, follow-up, evaluation, routine tests


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A Keshaviah, S Dellapasqua, N Rotmensz, J Lindtner, D Crivellari, J Collins, M Colleoni, B Thurlimann, C Mendiola, S Aebi, et al.
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Ann. Onc., April 1, 2007; 18(4): 701 - 708.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. J. Duffy
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Clin. Chem., March 1, 2006; 52(3): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Loprinzi, D. Hayes, and T. Smith
Doc, Shouldn't We Be Getting Some Tests?
J. Clin. Oncol., May 1, 2003; 21(90090): 108s - 111.
[Full Text] [PDF]

Home page
 JCOHome page
C. Garbe, A. Paul, H. Kohler-Spath, U. Ellwanger, W. Stroebel, M. Schwarz, B. Schlagenhauff, F. Meier, B. Schittek, H.-J. Blaheta, et al.
Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up Strategy
J. Clin. Oncol., February 1, 2003; 21(3): 520 - 529.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Loprinzi, D. Hayes, and T. Smith
Doc, Shouldn't We Be Getting Some Tests?
J. Clin. Oncol., June 11, 2000; 18(11): 2345 - 2348.
[Full Text] [PDF]

Home page
 CMAJHome page
L. K.F. Temple, E. E.L. Wang, and R. S. McLeod
Preventive health care, 1999 update: 3. Follow-up after breast cancer
Can. Med. Assoc. J., October 1, 1999; 161(8): 1001 - 1008.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.